173 related articles for article (PubMed ID: 18667806)
21. Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery.
Luca T; Givogri MI; Perani L; Galbiati F; Follenzi A; Naldini L; Bongarzone ER
Mol Ther; 2005 Oct; 12(4):669-79. PubMed ID: 16087406
[TBL] [Abstract][Full Text] [Related]
22. Intrinsic resistance of neural stem cells to toxic metabolites may make them well suited for cell non-autonomous disorders: evidence from a mouse model of Krabbe leukodystrophy.
Taylor RM; Lee JP; Palacino JJ; Bower KA; Li J; Vanier MT; Wenger DA; Sidman RL; Snyder EY
J Neurochem; 2006 Jun; 97(6):1585-99. PubMed ID: 16805770
[TBL] [Abstract][Full Text] [Related]
23. Elevated sulfatide excretion in heterozygotes of metachromatic leukodystrophy: dependence on reduction of arylsulfatase A activity.
Molzer B; Sundt-Heller R; Kainz-Korschinsky M; Zobel M
Am J Med Genet; 1992 Nov; 44(4):523-6. PubMed ID: 1359786
[TBL] [Abstract][Full Text] [Related]
24. Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy.
Capotondo A; Cesani M; Pepe S; Fasano S; Gregori S; Tononi L; Venneri MA; Brambilla R; Quattrini A; Ballabio A; Cosma MP; Naldini L; Biffi A
Hum Gene Ther; 2007 Sep; 18(9):821-36. PubMed ID: 17845130
[TBL] [Abstract][Full Text] [Related]
25. Developing therapeutic approaches for metachromatic leukodystrophy.
Patil SA; Maegawa GH
Drug Des Devel Ther; 2013; 7():729-45. PubMed ID: 23966770
[TBL] [Abstract][Full Text] [Related]
26. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice.
Consiglio A; Quattrini A; Martino S; Bensadoun JC; Dolcetta D; Trojani A; Benaglia G; Marchesini S; Cestari V; Oliverio A; Bordignon C; Naldini L
Nat Med; 2001 Mar; 7(3):310-6. PubMed ID: 11231629
[TBL] [Abstract][Full Text] [Related]
27. Lysosomal sulfatide storage in the brain of arylsulfatase A-deficient mice: cellular alterations and topographic distribution.
Wittke D; Hartmann D; Gieselmann V; Lüllmann-Rauch R
Acta Neuropathol; 2004 Oct; 108(4):261-71. PubMed ID: 15322834
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations.
Matzner U; Hartmann D; Lüllmann-Rauch R; Coenen R; Rothert F; Månsson JE; Fredman P; D'Hooge R; De Deyn PP; Gieselmann V
Gene Ther; 2002 Jan; 9(1):53-63. PubMed ID: 11850723
[TBL] [Abstract][Full Text] [Related]
29. Metachromatic leukodystrophy and pseudoarylsulfatase A deficiency in a Danish family.
Tønnesen T; Bro PV; Brøndum Nielsen K; Lykkelund C
Acta Paediatr Scand; 1983 Mar; 72(2):175-8. PubMed ID: 6132516
[TBL] [Abstract][Full Text] [Related]
30. Atidarsagene autotemcel for metachromatic leukodystrophy.
Messina M; Gissen P
Drugs Today (Barc); 2023 Feb; 59(2):63-70. PubMed ID: 36811406
[TBL] [Abstract][Full Text] [Related]
31. Deletion of fatty acid amide hydrolase reduces lyso-sulfatide levels but exacerbates metachromatic leukodystrophy in mice.
Yaghootfam C; Gehrig B; Sylvester M; Gieselmann V; Matzner U
J Biol Chem; 2021 Sep; 297(3):101064. PubMed ID: 34375644
[TBL] [Abstract][Full Text] [Related]
32. Partial cure of established disease in an animal model of metachromatic leukodystrophy after intracerebral adeno-associated virus-mediated gene transfer.
Sevin C; Verot L; Benraiss A; Van Dam D; Bonnin D; Nagels G; Fouquet F; Gieselmann V; Vanier MT; De Deyn PP; Aubourg P; Cartier N
Gene Ther; 2007 Mar; 14(5):405-14. PubMed ID: 17093507
[TBL] [Abstract][Full Text] [Related]
33. In vitro correction of ARSA deficiency in human skin fibroblasts from metachromatic leukodystrophy patients after treatment with microencapsulated recombinant cells.
Lagranha VL; Baldo G; de Carvalho TG; Burin M; Saraiva-Pereira ML; Matte U; Giugliani R
Metab Brain Dis; 2008 Dec; 23(4):469-84. PubMed ID: 18797988
[TBL] [Abstract][Full Text] [Related]
34. Fetal metachromatic leukodystrophy: pathology, biochemistry and a study of in vitro enzyme replacement in CNS tissue.
Poduslo SE; Tennekoon G; Price D; Miller K; McKhann GM
J Neuropathol Exp Neurol; 1976; 35(6):622-32. PubMed ID: 11278
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein E genotype and LRP1 polymorphisms in patients with different clinical types of metachromatic leukodystrophy.
Ługowska A; Musielak M; Jamroz E; Pyrkosz A; Kmieć T; Tylki-Szymańska A; Bednarska-Makaruk M
Gene; 2013 Sep; 526(2):176-81. PubMed ID: 23701968
[TBL] [Abstract][Full Text] [Related]
36. Brain cell type-specific endocytosis of arylsulfatase A identifies limitations of enzyme-based therapies for metachromatic leukodystrophy.
Kaminski D; Yaghootfam C; Matthes F; Reßing A; Gieselmann V; Matzner U
Hum Mol Genet; 2021 Feb; 29(23):3807-3817. PubMed ID: 33367737
[TBL] [Abstract][Full Text] [Related]
37. Successful transduction of oligodendrocytes and restoration of arylsulfatase A deficiency in metachromatic leukodystrophy fibroblasts using an adenovirus vector.
Ohashi T; Watabe K; Sato Y; Saito I; Barranger JA; Eto Y
Gene Ther; 1995 Sep; 2(7):443-9. PubMed ID: 7584122
[TBL] [Abstract][Full Text] [Related]
38. Genotypic characterization of Brazilian patients with infantile and juvenile forms of metachromatic leukodystrophy.
Virgens MY; Siebert M; Bock H; Burin M; Giugliani R; Saraiva-Pereira ML
Gene; 2015 Aug; 568(1):69-75. PubMed ID: 25965562
[TBL] [Abstract][Full Text] [Related]
39. Sixteen novel mutations in the arylsulfatase A gene causing metachromatic leukodystrophy.
Luzi P; Rafi MA; Rao HZ; Wenger DA
Gene; 2013 Nov; 530(2):323-8. PubMed ID: 24001781
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age.
Matthes F; Stroobants S; Gerlach D; Wohlenberg C; Wessig C; Fogh J; Gieselmann V; Eckhardt M; D'Hooge R; Matzner U
Hum Mol Genet; 2012 Jun; 21(11):2599-609. PubMed ID: 22388935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
